Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023
Background: Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear. Objectives: The current study aimed to evaluate the treatment features across various immunoth...
Saved in:
| Main Authors: | Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino, Mikako Tamba, Shohei Udagawa, Hiroki Osumi, Shota Fukuoka, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251322670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
by: Koshiro Fukuda, et al.
Published: (2025-04-01) -
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
by: Mikako Tamba, et al.
Published: (2025-04-01) -
Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma
by: M. Tamba, et al.
Published: (2025-06-01) -
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy
by: S. Udagawa, et al.
Published: (2025-06-01) -
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond
by: Kazumasa Yamamoto, et al.
Published: (2025-06-01)